View Author
stent patient group sirolimus-eluting sirolimus-eluting stents lesion follow-up target trial restenosi study revascularization circulation artery ravel target lesion 3 years month vessel randomized event control group sirolimu implantation sirolimus-eluting stent group outcome angiographic sirolimus-eluting stent neointimal diabetes mellitus metal stents intravascular table ultrasound procedure percutaneou volume abizaid treatment death diabetes control diameter result in-stent sousa popma jj ravel trial survival stenosi metal diabetic angiography bare-metal stents angina serruys pw non-diabetic difference in-stent restenosis sao paulo mellitu falotico r analysis failure intravascular ultrasound follow-up target lesion revascularization neointimal proliferation luminal diameter proliferation 6 months fajadet stent implantation serruy diabetic-ses group france bare-metal angioplasty hyperplasia point popma
2 Most Recent Publications
|
Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.
(Article)
Fajadet, J. Morice, M-C. Laarman, G-J. Perin, M.A. Sousa, J.E. Schuler, G. Molnar, F. Guagliumi, G. Colombo, A. Ban Hayashi, E. Wülfert, E. Barragan, P. Serruys, P.W.J.C. Wijns, W. Constantini, C. Guermonprez, J-L. Eltchaninoff, H. Blanchard, D. Bartorelli, A. |
2005-03-01
|
|
Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial
(Article)
Eltchaninoff, H. Guagliumi, G. Blanchard, D. Serruys, P.W.J.C. Abizaid, A.C. Albertal, M. Laarman, G-J. Morice, M-C. Abizaid, A.S. Sousa, A.G.M.R. Wülfert, E. Sousa, J.E. Lindeboom, W.K. Costa, M.A. |
2004-01-01
|
